Emtricitabine

Breastfeeding
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Ganciclovir, Lamivudine, Ribavirin, Valganciclovir

PREGNANCY CATEGORY: B

Emtricitabine is a fluorinated derivative of lamivudine.

Atripla is emtricitabine, efavirenz and tenofovir disoproxil; Complera is emtricitabine, rilpivirine and tenofovir disoproxil; Descovy is emtricitabine and tenofovir alafenamide; Truvada is emtricitabine and tenofovir disoproxil.

See also separate profiles for emtricitabine in combination with cobicistat, elvitegravir and tenofovir disoproxil or tenofovir alafenamide.

LACTIC ACIDOSIS / SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS B

See full prescribing information for complete boxed warning.

Our database has 55 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
OTIC
RENAL
RESPIRATORY
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of emtricitabine with tenofovir disoproxil in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top